Hormonal Regulation of the Vitamin D Receptor in Human Breast Cancer Cells: A Novel Strategy for Augmenting the Antiproliferative Effects of Calcitriol.
Abstract
The T47D human breast cancer cell line was grown in triplicate for 7 days in the presence or absence of the following hormonal treatments: estradiol (10-6-10-9M), tamoxifen (10-7M) or tamoxifen (10-7-10-9M) with 10-8M estradiol, calcitriol (10-8M), cortisone (10-7-10-9M), triiodothyronine(10-7-10-9M), progesterone (10-6-10-10M), testosterone(10-6-10-10M), retinoic acid (10-6-10-10M), or dexamethasone (10-710-9M) - No consistent dose-related effect on the growth was observed. The following human cell lines were screened in triplicate for the effect of calcitriol (10-8 M) on cell growth: T47D, CRL-1500, CRL-1897, HTB-20, HTB-23, HTB-24, HTB-26, HTB-27, HTB-30, HTB-122, HTB-126, HTB-131. Again, no consistent effect on cell growth was observed. The presence of the vitamin D receptor was verified in T47D, HTB-20, and CRLlSOO cells by PCR. To further investigate the action of more potent calcitriol analogues on cell growth, T47D, MCF-7, HTB-20, and HTB-131 cells were exposed to calcitriol, 22- oxacalcitriol, l6ene-calcitriol, and l6ene, 23 yne-calcitriol. Cellular proliferation was assessed in these experiments by 3H-thymidine incorporation and all treatments were done in triplicate or quadruplicate. No antiproliferative effect of calcitriol or its analogues over a 6 log concentration range was observed in any cell line tested. Calcitriol does not appear to be a modulator of cell growth in cultured human breast cancer cells and the use of calcitriol or its analogues does not appear to be a promising approach to therapy of breast cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- Feb 15, 1995
- Accession Number
- ADA292688
Entities
People
- William E. Duncan
Organizations
- Walter Reed Army Medical Center